8-K
filed November 14, 2022, 6:59 PM ET
ticker VBIO
CIK 0001787740
earnings
confidence high
sentiment positive
materiality 0.70
Tivic Health Q3 revenue up 72% to $477K; net loss $2.6M; agrees to acquire Reliefband for $33.5M
Valion Bio, Inc.
2022-Q3 EPS reported
-$0.81
revenue$1,432,000
- Q3 2022 revenue $477K (+72% YoY); DTC unit sales up 130%; gross margin improved 22%.
- Net loss $2.6M vs $2.3M in Q3 2021; cash and short-term investments $6.3M at Sept 30, 2022.
- Entered asset purchase agreement for Reliefband (nausea treatment devices) for $33.5M cash; expected close Q4 2022/Q1 2023.
- Manufacturing agreement with Microart to reduce ClearUP production costs; MSRP increased $20/unit.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Valion Bio, Inc. reported the quarter ended September 30, 2022 results: revenue $477 thousand, net income $2.6 million.
- Period
- the quarter ended September 30, 2022
- Revenue
- $477 thousand
- Net income
- $2.6 million
- Result
- reported results
Exact text from the filing
Third Quarter 2022 Financial Highlights (as compared to the same periods in 2021) For the three months ended September 30, 2022: • Revenue increased 72% from $277 thousand to $477 thousand
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Valion Bio, Inc. reported the nine months ended September 30, 2022 results: revenue $1.4 million.
- Period
- the nine months ended September 30, 2022
- Revenue
- $1.4 million
- Result
- reported results
Exact text from the filing
For the nine months ended September 30, 2022: • Revenue increased $65% from $868 thousand to $1.4 million
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.